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FK 506 in the Management of Nephrotic Syndrome After 
Renal Transplantation 
J. McCauley, R. Shapiro, M. Jordan, V. Scantlebury, C. Vivas, C. Jensen, and T.E. Starzl 
N EPHROTIC syndrome developing after renal trans-plantation has many etiologies. Recurrent focal scle-
rosing glomerulonephritis is' ane of the leading causes.! 
Other etiologies include: (1) transplant glomerulopathy; (2) 
chronic rejection; (3) de novo membranous glomerulone-
phritis (ON); and (4) other recurrent glomerulonephropa-
thies (membranoproliferative glomerulonephritis [MPGN] , 
systemic lupus erythematosus [SLE], diabetes, etc).2 The 
important treatment goals for these patients are to control 
the metabolic consequences of nephrotic syndrome and 
delay or prevent progression of renal failure. None of these 
diseases has been successfully treated after transplantation 
with the therapies conventionally used for native kidney 
ON. After a dramatic improvement in proteinuria in a 
patient with de novo focal segmental glomerulosclerosis 
(FSGS). we embarked on a limited pilot trial to determine 
if FK 506 might be helpful in managing these patients.3 
Because this was a probing effort. no patient with post-
transplant nephrotic syndrome was eliminated from con-
sideration. This diverse group of histological lesions might 
reproduce the immunologic mediators of the primary dis-
ease that developed in the patient's native kidneys or 
initiate a wholly different set of immune processes that 
result in a totally different form of GN.4 Posttransplant 
glomerulopathies may provide a unique opportunity to 
investigate the determinants of glomerular injury. 
PATIENTS AND METHODS 
From March 1990 until May 1992,24 patients with posttransplant 
nephrotic syndrome were converted from cyclosporine A (eyA) 
to FK 506. Approximately half the patients were initially trans-
planted at the University of Pittsburgh; the remainder were 
referred to the University of Pittsburgh specifically for manage-
ment of the nephrotic syndrome with FK 506. The criteria for 
entry into this study were serum creatinine (Ser) <6.0 and the 
presence of nephrotic range proteinuria. Baseline graft biopsies 
were performed in all cases. 
Immunosuppression Protocols 
All patients were receiving eyA and prednisone immunosuppres-
sion; most also received imuran. eyA was stopped 24 hours or the 
evening prior (12 hours) to conversion if no rejection was noted on 
baseline biopsies. The initial conversion FK 506 dose was .3 
mglkgld given in two divided doses. After approximately six 
patients, the dose of FK 506 was lowered to .2 mglkgld in divided 
doses. This reduction in dosage was primarily due to significant 
nephrotoxicity and other symptoms of excessive FK 506 therapy. 
The starting dose was later lowered to .15 mglkgld twice per day 
if rejection was absent at the time of conversion. If moderate 
rejection was present on pretreatment biopsies, a dose of .2 to .3 
mglkgld given twice was used. One patient with moderate rejec-
tion received intravenous solumedrol at the time of conversion. 
Imuran was discontinued in the first cases but continued in the 
most recent patients in an attempt to reduce the dose of FK 506 
required and the accompanying nephrotoxicity. The prednisone 
dose was initially reduced by approximately one half at the time of 
conversion in the early cases. The prednisone dose is now 
continued unchanged unless rejection is detected on pretreatment 
biopsies. 
Patient Groups by Pretreatment Graft Biopsy 
Based upon pretreatment biopsies, patients were classified into 
four groups: (1) FSGS (10 patients); (2) recurrent lupus nephrop-
athy (2 patients); (3) chronic rejection (II patients); (4) de novo 
membranous GN (I patient). One of the patients with FSGS had 
de novo FSGS; his native kidney disease was polycystic kidney 
disease. One patient with chronic rejection also had evidence for 
transplant glomerulopathy, but the latter was not felt to be the 
predominant lesion. 
Definition of Outcomes 
Patients were considered improved if 24-hour protein excretion 
was reduced by at least 50% and Ser was < 1.5 mg/dL greater 
than baseline values. Patients were considered to have failed 
therapy if 24-hour protein excretion had not declined by at least 
50%. If Ser increased >2.0 mg/dL or was progressively increas-
ing, patients were considered to have failed. Any patient requiring 
dialysis or retransplantation was considered to have failed. Dif-
ferences between means were determin"d by Student's I test or 
analysis of variance when appropriate. 
RESULTS 
Our experience in converting renal transplant patients 
from CyA to FK 506 was encouraged by the clinical 
outcome of our first patient; his clinical course is illus-
trated in Fig 1. This patient. with a history of polycystic 
kidney disease. developed de novo FSGS with significant 
mesangial proliferation and mild acute cellular rejection 
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Fig 1. Clinical course of the first 
patient treated converted from 
CyA to FK 506 for nephrotic syn-
drome. 
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(ACR) on a pretreatment biopsy. Simple conversion from 
Cy A to FK 506 resulted in a rapid and sustained fall in 
proteinuria without deterioration in renal function. These 
encouraging results led us to explore a potential role for 
this drug in managing nephrotic syndrome after renal 
transplantation. 
The clinical outcomes in all patients by pretreatment 
renal histology are illustrated in Fig 2. Twenty-four-hour 
protein excretions were: FSGS (7.2 ± 1.2 g pretreatment 
to 3.9 ± 2.9); recurrent SLE (5.4 ± 2.5 pre and 2.6 ± 2.4 
post); and chronic rejection (8.5 ± 1.3 pre and 5.6 ± 1.9 
post). There was no significant difference in pretreatment 
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FSGS 
or latest 24-hour protein excretion between groups al-
though patient numbers were small. Only 1 of the 11 
patients with FSGS was found to improve. 6 of 10 patients 
with FSGS. Neither of the two patients with SLE im-
proved and the patient with de novo membranous GN has 
experienced a 50% fall in proteinuria after 2 months of 
therapy. 
The changes in renal function by pretreatment histology 
are demonstrated in Fig 3. Pretreatment and latest SCr 
were: FSGS (1.9 ± 0.2 to 1.8 ± 0.4 mgldL); SLE (1.85 ± 
0.35 to 5.6 ± 2.4 mgldL); and chronic rejection (2.7 ± 0.4 
to 5.5 ± 1.0 mg/dL). P < .05 FSGS pre and post vs chronic 
SLE CHRON REJ Fig 2. Urinary protein excretion 
by pretreatment allograft biopsy. 
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FSGS SLE CHRON REJ Fig 3. Serum creatinine after 
conversion to FK 506. Error bars 
are:t SEM. _ PRE-FKS06 _ LATEST 
rejection. The 10 patients with chronic rejection have 
progressed to require dialysis or retransplantation. The 
sole patient with improved protein excretion died of a 
subarachnoid hemorrhage after 3 months of therapy. Both 
of the patients with SLE are awaiting retransplantation 
although neither has started dialysis to date. Four of the 
six patients with FSGS have been treated for approxi-
mately 2 months. Two of the patients who failed had been 
converted after rapid recurrence of FSGS after transplan-
tation. Institution of FK 506 therapy had no beneficial 
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effect on the patients' proteinuria and both ultimately 
required nephrectomy. 
The contribution of graft rejection on pretreatment bi-
opsies to protein excretion is depicted in Fig 4. Patients 
with mild ACR experienced the greatest fall in protein 
excretion. Patients with moderate ACR or none had insig-
nificant changes in proteinuria. Pretreatment and latest 
SCr by degree of rejection were: no ACR (2.54 ± 0.8 to 3.2 
± 1.0 mgldL); mild ACR (2.1 ± 0.26 to 3.7 ± 0.9 mgldL); 
and moderate ACR (2.6 ± 0.8 to 9.0 ± 1.0 mgldL). 
NONE MILD MODERATE 
Fig 4. Urinary protein excretion 
by degree of ACR on pretreat-
ment allograft biopsies. Error 
bars are :t SEM. 
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DISCUSSION 
Our growing experience with FK 506 in posttransplant 
nephrotic syndrome has revealed the limitations of this 
therapy and further defined the characteristics of the group 
of patients who are likely to benefit. Patients with chronic 
rejection of any degree on preconversion biopsies univer-
sally fail to benefit and progress to end-stage renal disease 
or retransplantation. The presence of chronic rejection is 
probably an absolute contraindication for conversion to 
FK 506. These patients usually have advanced renal 
disease and apparently possess a nonimmunologic patho-
physiological process that is irreversible. The speculated 
role of interleukin (IL)-l in this process may also explain 
the lack of effectiveness of an agent that is primarily an 
IL-2 inhibitor.5 Neither rapidly recurrent FSGS nor recur-
rent SLE improved with FK 506. The lack of responsive-
ness of these lesions is probably due to persistent immu-
nologic factors, such as cytokine activation and persistent 
antibody production, that are not under the control of Cy A 
or FK 506. 
More encouraging results have been demonstrated in 
patients with de novo FSGS after transplantation. FSGS 
has been associated with increased IL-l, IL-2, and IL-8 
production that may, at least in part. be inhibited by FK 
506 in the early developmental stages. (HI Mild ACR as so-
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ciated with mesangial proliferation appears to be the most 
promising setting for FK 506 conversion. Interestingly, the 
absence of ACR or moderate ACR carried a worse prog-
nosis. 
The use of FK 506 after renal transplantation is likely to 
be helpful in managing the nephrotic syndrome in a well-
defined population of patients. Investigation of the deter-
minants of responsiveness to FK 506 offers the opportu-
nity to more fully uncover the causes of nephrotic 
syndrome both after transplantation and in native kidney 
glomerulonephritis. 
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